Compare AbCellera Biologics Inc (ABCL) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

REMX trades at $85.34, down 1.59% today, with a bearish technical signal driven by moving averages. The ETF is positioned in the rare earth and strategic metals sector, benefiting from geopolitical tensions and supply chain shifts. Recent news highlights strong institutional interest in materials and commodities, with REMX recognized for AI infrastructure and defense exposure. Key support is at $84, with resistance at $86.

Outlook is mixed; rare earth demand is rising due to AI and energy transitions, but high concentration and volatility pose risks. Investment opportunity lies in commodity cycle exposure, yet investors face geopolitical and inflation uncertainties. Wall Street sentiment is cautious despite thematic tailwinds.